Symbols / XTLB
XTLB Chart
About
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.32M |
| Enterprise Value | 704.76M | Income | -6.31M | Sales | 968.00K |
| Book/sh | -0.00 | Cash/sh | 259000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 10 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 7.57 | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | 728.06 | Quick Ratio | 0.46 |
| Current Ratio | 0.70 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.90 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2016-06-01 08:00 | ROA | -240.56% |
| ROE | -5.77% | ROIC | — | Gross Margin | -232.85% |
| Oper. Margin | -8.54% | Profit Margin | 0.00% | Shs Outstand | 9.46M |
| Shs Float | 481.32M | Short Float | 2.89% | Short Ratio | 0.11 |
| Short Interest | — | 52W High | 2.57 | 52W Low | 0.53 |
| Beta | 0.81 | Avg Volume | 729.17K | Volume | 1.11K |
| Target Price | — | Recom | None | Prev Close | $0.80 |
| Price | $0.77 | Change | -3.23% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.77
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
$0.77
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2015-05-08 | init | HC Wainwright & Co. | — → Buy | $6 |
- XTL Biopharmaceuticals Shareholders Approve Capital Increase and NeuroNOS-Linked Private Placement - TipRanks ue, 24 Feb 2026 21
- XTL Biopharmaceuticals Ltd. Receives Nasdaq Non-Compliance Notification Regarding Stockholders' Equity Requirements | XTLB Stock News - Quiver Quantitative Fri, 23 Jan 2026 08
- Nasdaq notice hits XTL Biopharma over sub-$2.5M equity level - Stock Titan Fri, 23 Jan 2026 08
- XTL Biopharmaceuticals Adjourns Extraordinary Shareholders Meeting for Lack of Quorum - The Globe and Mail Wed, 18 Feb 2026 08
- XTL Biopharmaceuticals announces CFO transition amid strategic appointments - MSN ue, 03 Feb 2026 19
- XTL Biopharmaceuticals: Shifting Gears or Grounded Reality? - StocksToTrade Wed, 08 Oct 2025 07
- Nasdaq flags small drugmaker after shares trade under $1 - Stock Titan Wed, 24 Dec 2025 08
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga ue, 17 Feb 2026 12
- XTL Biopharmaceuticals Ltd. Announces Acquisition Efforts for 85% Stake in NeuroNOS Ltd. and Upcoming Shareholders Meeting - Quiver Quantitative hu, 29 Jan 2026 08
- XTL Biopharmaceuticals schedules extraordinary general meeting for February - Investing.com ue, 13 Jan 2026 08
- Wolfe’s Chris Caso, Who Bet On Micron, Says This AI Stock Has A Competitive Advantage That “Even Google Can't Match” - Stocktwits ue, 13 Jan 2026 08
- Two Nobel laureates back new autism drug effort in XTL’s NeuroNOS deal - Stock Titan ue, 13 Jan 2026 08
- XTL Biopharmaceuticals Acquires 85% of NeuroNOS to Advance Autism Therapeutics with Leading Scientific Team - Quiver Quantitative ue, 13 Jan 2026 08
- XTL Biopharmaceuticals Moves to Acquire NeuroNOS Stake from Beyond Air and Plans $2 Million Private Placement - TipRanks ue, 13 Jan 2026 08
- Two Nobel winners back new autism drug push with XTL NeuroNOS deal - Stock Titan ue, 13 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 119.89K | 0.00 | 0.00 | 340.17K |
| TaxRateForCalcs | 0.11 | 0.00 | 0.00 | 0.23 |
| NormalizedEBITDA | -2.00M | -728.00K | -854.00K | -2.51M |
| TotalUnusualItems | 1.07M | -1.05M | -493.00K | 1.48M |
| TotalUnusualItemsExcludingGoodwill | 1.07M | -1.05M | -493.00K | 1.48M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -1.03M | -1.78M | -1.35M | 435.00K |
| ReconciledDepreciation | 199.00K | 0.00 | 1.00K | 1.00K |
| ReconciledCostOfRevenue | 280.00K | 0.00 | 0.00 | |
| EBITDA | -930.00K | -1.78M | -1.35M | -1.03M |
| EBIT | -1.13M | -1.78M | -1.35M | -1.03M |
| NetInterestIncome | -52.00K | 37.00K | 25.00K | -13.00K |
| InterestExpense | 28.00K | 0.00 | 0.00 | |
| InterestIncome | 34.00K | 41.00K | 36.00K | 8.00K |
| NormalizedIncome | -1.97M | -728.00K | -855.00K | -703.83K |
| NetIncomeFromContinuingAndDiscontinuedOperation | -1.03M | -1.78M | -1.35M | 435.00K |
| TotalExpenses | 2.62M | 765.00K | 880.00K | 1.03M |
| RentExpenseSupplemental | 27.00K | 12.00K | 6.00K | 15.00K |
| TotalOperatingIncomeAsReported | -2.17M | -765.00K | -880.00K | -1.03M |
| DilutedAverageShares | 7.04M | 5.45M | 5.45M | 6.16M |
| BasicAverageShares | 6.73M | 5.45M | 5.45M | 5.32M |
| DilutedEPS | -0.30 | -0.30 | -0.20 | -0.04 |
| BasicEPS | -0.20 | -0.30 | -0.20 | 0.10 |
| DilutedNIAvailtoComStockholders | -1.03M | -1.78M | -1.35M | -225.00K |
| AverageDilutionEarnings | 0.00 | 0.00 | -660.00K | |
| NetIncomeCommonStockholders | -1.03M | -1.78M | -1.35M | 435.00K |
| NetIncome | -1.03M | -1.78M | -1.35M | 435.00K |
| NetIncomeIncludingNoncontrollingInterests | -1.03M | -1.78M | -1.35M | 435.00K |
| NetIncomeContinuousOperations | -1.03M | -1.78M | -1.35M | 435.00K |
| TaxProvision | -130.00K | 0.00 | 0.00 | |
| PretaxIncome | -1.16M | -1.78M | -1.35M | 435.00K |
| OtherIncomeExpense | 1.07M | -1.05M | -493.00K | 1.48M |
| GainOnSaleOfSecurity | 1.07M | -1.05M | -493.00K | 1.48M |
| NetNonOperatingInterestIncomeExpense | -52.00K | 37.00K | 25.00K | -13.00K |
| TotalOtherFinanceCost | 58.00K | 4.00K | 11.00K | 21.00K |
| InterestExpenseNonOperating | 28.00K | 0.00 | 0.00 | |
| InterestIncomeNonOperating | 34.00K | 41.00K | 36.00K | 8.00K |
| OperatingIncome | -2.17M | -765.00K | -880.00K | -1.03M |
| OperatingExpense | 2.17M | 765.00K | 880.00K | 1.03M |
| DepreciationAmortizationDepletionIncomeStatement | 31.00K | 0.00 | 0.00 | |
| DepreciationAndAmortizationInIncomeStatement | 31.00K | 0.00 | 0.00 | |
| Amortization | 31.00K | 0.00 | 0.00 | |
| AmortizationOfIntangiblesIncomeStatement | 31.00K | 0.00 | 0.00 | |
| ResearchAndDevelopment | 98.00K | 31.00K | 30.00K | 30.00K |
| SellingGeneralAndAdministration | 2.05M | 734.00K | 850.00K | 1.00M |
| SellingAndMarketingExpense | 178.00K | 0.00 | 0.00 | |
| GeneralAndAdministrativeExpense | 1.87M | 734.00K | 850.00K | 1.00M |
| OtherGandA | 897.00K | 433.00K | 443.00K | 656.00K |
| InsuranceAndClaims | 100.00K | 119.00K | 202.00K | 229.00K |
| RentAndLandingFees | 27.00K | 12.00K | 6.00K | 15.00K |
| SalariesAndWages | 844.00K | 170.00K | 199.00K | 101.00K |
| GrossProfit | 3.00K | 0.00 | 0.00 | |
| CostOfRevenue | 448.00K | 0.00 | 0.00 | |
| TotalRevenue | 451.00K | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 451.00K | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 881.39M | 544.91M | 544.91M | 544.91M |
| ShareIssued | 881.39M | 544.91M | 544.91M | 544.91M |
| TotalDebt | 138.00K | |||
| TangibleBookValue | -1.57M | 1.84M | 3.62M | 4.95M |
| InvestedCapital | 5.57M | 2.22M | 4.00M | 5.33M |
| WorkingCapital | -867.00K | 1.84M | 3.62M | 6.01M |
| NetTangibleAssets | -1.57M | 1.84M | 3.62M | 4.95M |
| CommonStockEquity | 5.43M | 2.22M | 4.00M | 5.33M |
| TotalCapitalization | 5.43M | 2.22M | 4.00M | 5.33M |
| TotalEquityGrossMinorityInterest | 5.43M | 2.22M | 4.00M | 5.33M |
| StockholdersEquity | 5.43M | 2.22M | 4.00M | 5.33M |
| GainsLossesNotAffectingRetainedEarnings | 20.00K | 20.00K | 20.00K | 20.00K |
| OtherEquityAdjustments | 20.00K | 20.00K | 20.00K | 20.00K |
| RetainedEarnings | -159.01M | -158.25M | -156.47M | -155.13M |
| AdditionalPaidInCapital | 141.29M | 146.33M | 146.33M | 146.33M |
| CapitalStock | 23.14M | 14.12M | 14.12M | 14.12M |
| CommonStock | 23.14M | 14.12M | 14.12M | 14.12M |
| TotalLiabilitiesNetMinorityInterest | 3.12M | 206.00K | 187.00K | 1.28M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 908.00K | 0.00 | 0.00 | 1.05M |
| DerivativeProductLiabilities | 689.00K | 0.00 | 0.00 | 1.05M |
| NonCurrentDeferredLiabilities | 219.00K | 0.00 | ||
| NonCurrentDeferredTaxesLiabilities | 219.00K | 0.00 | ||
| CurrentLiabilities | 2.21M | 206.00K | 187.00K | 231.00K |
| OtherCurrentLiabilities | 1.28M | |||
| CurrentDeferredLiabilities | 18.00K | 0.00 | ||
| CurrentDeferredRevenue | 18.00K | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 138.00K | |||
| CurrentDebt | 138.00K | |||
| LineOfCredit | 138.00K | 0.00 | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 53.00K | 0.00 | ||
| PayablesAndAccruedExpenses | 719.00K | 206.00K | 187.00K | 231.00K |
| CurrentAccruedExpenses | 492.00K | 205.00K | 185.00K | 229.00K |
| Payables | 227.00K | 1.00K | 2.00K | 2.00K |
| OtherPayable | 31.00K | |||
| AccountsPayable | 196.00K | 1.00K | 2.00K | 2.00K |
| TotalAssets | 8.55M | 2.43M | 4.19M | 6.62M |
| TotalNonCurrentAssets | 7.21M | 380.00K | 380.00K | 381.00K |
| InvestmentsAndAdvances | 14.00K | 0.00 | ||
| InvestmentinFinancialAssets | 14.00K | 0.00 | ||
| AvailableForSaleSecurities | 14.00K | |||
| GoodwillAndOtherIntangibleAssets | 7.01M | 380.00K | 380.00K | 380.00K |
| OtherIntangibleAssets | 3.82M | 380.00K | 380.00K | 380.00K |
| Goodwill | 3.19M | 0.00 | ||
| NetPPE | 187.00K | 0.00 | 0.00 | 1.00K |
| CurrentAssets | 1.34M | 2.05M | 3.81M | 6.24M |
| OtherCurrentAssets | 47.00K | 11.00K | 14.00K | 16.00K |
| PrepaidAssets | 51.00K | 29.00K | 71.00K | 94.00K |
| Receivables | 150.00K | 29.00K | 71.00K | 94.00K |
| OtherReceivables | 51.00K | 29.00K | 71.00K | 94.00K |
| AccountsReceivable | 99.00K | 0.00 | ||
| AllowanceForDoubtfulAccountsReceivable | -36.00K | 0.00 | ||
| GrossAccountsReceivable | 135.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 1.14M | 2.01M | 3.72M | 6.13M |
| OtherShortTermInvestments | 772.00K | 605.00K | 1.63M | 3.16M |
| CashAndCashEquivalents | 371.00K | 1.40M | 2.09M | 2.97M |
| CashEquivalents | 0.00 | 1.27M | 681.00K | 2.37M |
| CashFinancial | 371.00K | 133.00K | 1.41M | 599.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -1.67M | -707.00K | -901.00K | -1.05M |
| RepaymentOfDebt | -13.00K | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 1.46M | 0.00 | 0.00 | |
| CapitalExpenditure | -54.00K | |||
| EndCashPosition | 371.00K | 1.40M | 2.09M | 2.97M |
| BeginningCashPosition | 1.40M | 2.09M | 2.97M | 3.63M |
| EffectOfExchangeRateChanges | -15.00K | -27.00K | -10.00K | -6.00K |
| ChangesInCash | -1.01M | -666.00K | -865.00K | -656.00K |
| FinancingCashFlow | 1.45M | 0.00 | 0.00 | 385.00K |
| CashFlowFromContinuingFinancingActivities | 1.45M | 0.00 | 0.00 | 385.00K |
| ProceedsFromStockOptionExercised | 0.00 | 0.00 | 385.00K | |
| NetCommonStockIssuance | 1.46M | 0.00 | 0.00 | |
| CommonStockIssuance | 1.46M | 0.00 | 0.00 | |
| NetIssuancePaymentsOfDebt | -13.00K | 0.00 | 0.00 | |
| NetShortTermDebtIssuance | -13.00K | 0.00 | 0.00 | |
| ShortTermDebtPayments | -13.00K | 0.00 | 0.00 | |
| InvestingCashFlow | -844.00K | 41.00K | 36.00K | 8.00K |
| CashFlowFromContinuingInvestingActivities | -844.00K | 41.00K | 36.00K | 8.00K |
| NetOtherInvestingChanges | -400.00K | |||
| InterestReceivedCFI | 34.00K | 41.00K | 36.00K | 8.00K |
| NetInvestmentPurchaseAndSale | -14.00K | 0.00 | 0.00 | 0.00 |
| SaleOfInvestment | 0.00 | |||
| PurchaseOfInvestment | -14.00K | 0.00 | 0.00 | |
| NetBusinessPurchaseAndSale | -410.00K | 0.00 | 0.00 | |
| PurchaseOfBusiness | -410.00K | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -54.00K | 0.00 | 0.00 | 0.00 |
| PurchaseOfPPE | -54.00K | 0.00 | 0.00 | 0.00 |
| OperatingCashFlow | -1.62M | -707.00K | -901.00K | -1.05M |
| CashFlowFromContinuingOperatingActivities | -1.62M | -707.00K | -901.00K | -1.05M |
| ChangeInWorkingCapital | 189.00K | 64.00K | -19.00K | -54.00K |
| ChangeInPayablesAndAccruedExpense | 208.00K | 19.00K | -44.00K | -23.00K |
| ChangeInPayable | 208.00K | 19.00K | -44.00K | -23.00K |
| ChangeInAccountPayable | 208.00K | 19.00K | -44.00K | -23.00K |
| ChangeInPrepaidAssets | -58.00K | 45.00K | 25.00K | -31.00K |
| ChangeInReceivables | 39.00K | 0.00 | 0.00 | |
| ChangesInAccountReceivables | 39.00K | 0.00 | 0.00 | |
| OtherNonCashItems | -20.00K | -14.00K | -26.00K | -8.00K |
| StockBasedCompensation | 264.00K | 3.00K | 14.00K | 37.00K |
| UnrealizedGainLossOnInvestmentSecurities | -167.00K | 1.02M | 1.53M | -747.00K |
| DeferredTax | -130.00K | 0.00 | 0.00 | |
| DeferredIncomeTax | -130.00K | 0.00 | 0.00 | |
| DepreciationAmortizationDepletion | 199.00K | 0.00 | 1.00K | 1.00K |
| DepreciationAndAmortization | 199.00K | 0.00 | 1.00K | 1.00K |
| Depreciation | 0.00 | 1.00K | 1.00K | |
| OperatingGainsLosses | -926.00K | 27.00K | -1.05M | -713.00K |
| GainLossOnInvestmentSecurities | -926.00K | -1.05M | -719.00K | |
| NetForeignCurrencyExchangeGainLoss | 27.00K | 10.00K | 6.00K | |
| NetIncomeFromContinuingOperations | -1.03M | -1.78M | -1.35M | 435.00K |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for XTLB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|